A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients — Julie Le Naour (2022) | RDL Network
A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients
Article 2022 en
Authors
JN
Julie Le Naour
ZS
Zsófia Sztupinszki
VC
Vincent Carbonnier
Abstract
1 min read
The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we investigated the impact of single nucleotide polymorphisms (SNPs) in genes affecting this cancer-immunity dialogue in the context of head and neck squamous cell carcinoma (HNSCC). We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients. This result was obtained on a cohort of patients enrolled at the Gustave Roussy Cancer Campus and was validated on an independent cohort of The Cancer Genome Atlas (TCGA). Homozygosity in rs2241880 is well known to predispose to Crohn's disease, and epidemiological associations between Crohn's disease and HNSCC have been reported at the levels of cancer incidence and prognosis. We speculate that rs2241880 might be partially responsible for this association.
Federica Iannelli, Andrea Ilaria Zotti, Maria Serena Roca, Laura Grumetti, Tania Moccia, Carlo Vitagliano, Susan Costantini, francesca capone, Francesca Collina, Lucia Gabriele, Stefania Parlato, Giulia Romagnoli, Oliver Kepp, Guido Guido Kroemer, Elena Di Gennaro, Alfredo Budillon
Discussion(0)
No comments yet. Be the first to comment.